Transnasal delivery of the peptide to the brain

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-B-111-Tuesday
• By: TANAKA, Akiko (Kyoto, Japan)
• Co-author(s): Akiko Tanaka: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Chiaki Maeda: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Mayumi Amano: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Kentaro Takayama: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
  Yoshio Hayashi: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
  Daisuke Inoue: School of Pharmacy, Shujitsu University, Okayama, Japan
  Tomoyuki Furubayashi: School of Pharmacy, Shujitsu University, Okayama, Japan
  Kosuke Kusamori: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Hidemasa Katsumi: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Toshiyasu Sakane: Department of Pharmaceutical Technology, Kobe Pharmaceutical University, Kobe, Japan;Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  Akira Yamamoto: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  
• Abstract:

  Backgrounds

  The obesity and the metabolic syndrome have prevailed all over the world. Recently, CPN-116 (CPN), which is a specific agonist peptide to neuromedin U receptor 2 (NMUR2), has been developed as a new therapeutic candidate for the treatments of obesity. The treatment with CPN will be unlikely successful due to the limited delivery to the..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login